Related Experiment Videos
Dexamethasone effects on somatostatin receptors in pancreatic acinar AR4-2J cells
N Viguerie1, J P Estève, C Susini
1INSERM U 151, Toulouse, France.
Abstract:
The effects of glucocorticoids on somatostatin binding and cAMP response in the rat pancreatic acinar carcinoma AR4-2J cell line were examined. Dexamethasone treatment reduced the number of somatostatin receptors 2.5 fold without any change in receptor affinity. In addition, dexamethasone increased the sensitivity of the cells to somatostatin-inhibited cAMP formation and restored the biphasic pattern of cAMP response to somatostatin previously observed in normal pancreatic acinar cells. Such effect may be associated with the glucocorticoid-promoted cellular pancreatic differentiation of AR4-2J cells.
Insights
Glucocorticoids like dexamethasone reduce somatostatin receptors but enhance cellular response to somatostatin in pancreatic cancer cells. This suggests a role in promoting pancreatic cell differentiation.
Area of Science:
- Endocrinology
- Cell Biology
- Cancer Research
Background:
- Pancreatic acinar carcinoma AR4-2J cells are a model for studying pancreatic cell function.
- Glucocorticoids are known to influence cellular processes and differentiation.
- Somatostatin plays a role in regulating pancreatic cell activity, including cAMP signaling.
Purpose of the Study:
- To investigate the impact of glucocorticoids on somatostatin binding and cAMP response in AR4-2J cells.
- To explore the potential link between glucocorticoid effects and pancreatic cellular differentiation.
Main Methods:
- Treatment of AR4-2J cells with dexamethasone.
- Measurement of somatostatin receptor number and affinity.
- Assessment of cyclic adenosine monophosphate (cAMP) response to somatostatin.
Main Results:
- Dexamethasone significantly reduced somatostatin receptor number by 2.5-fold without altering receptor affinity.
- Dexamethasone increased AR4-2J cell sensitivity to somatostatin-mediated inhibition of cAMP.
- Dexamethasone restored a biphasic cAMP response pattern to somatostatin, mimicking normal pancreatic acinar cells.
Conclusions:
- Glucocorticoid treatment, specifically with dexamethasone, modulates somatostatin receptor dynamics and signaling in pancreatic cancer cells.
- These effects may be attributed to glucocorticoid-induced cellular pancreatic differentiation in AR4-2J cells.
- Findings provide insights into the endocrine regulation of pancreatic cancer cell behavior.